▼Glycopyrronium powder for inhalation (Seebri Breezhaler—Novartis) is a long-acting muscarinic receptor antagonist (LAMA), licensed as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).1 This is the third long-acting agent that has recently been licensed in the UK for use in people with COPD (see ▼Indacaterol for COPD2 and ▼Aclidinium for COPD?3). The company's promotional material claims that ‘Seebri is a once daily LAMA which supports cost effective prescribing at all stages of COPD’.4 In this article we review the evidence for glycopyrronium and assess its place in the management of COPD.